These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35875160)

  • 1. Low expression and Hypermethylation of ATP2B1 in Intrahepatic Cholangiocarcinoma Correlated With Cold Tumor Microenvironment.
    Zhang X; He Y; Ren P; Chen L; Han Z; Qi L; Chen L; Luo Y; Zhang N; Lu W; Guo H
    Front Oncol; 2022; 12():927298. PubMed ID: 35875160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma.
    Job S; Rapoud D; Dos Santos A; Gonzalez P; Desterke C; Pascal G; Elarouci N; Ayadi M; Adam R; Azoulay D; Castaing D; Vibert E; Cherqui D; Samuel D; Sa Cuhna A; Marchio A; Pineau P; Guettier C; de Reyniès A; Faivre J
    Hepatology; 2020 Sep; 72(3):965-981. PubMed ID: 31875970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphocyte-C-reactive protein ratio as a prognostic marker associated with the tumor immune microenvironment in intrahepatic cholangiocarcinoma.
    Yugawa K; Itoh S; Yoshizumi T; Morinaga A; Iseda N; Toshima T; Harada N; Kohashi K; Oda Y; Mori M
    Int J Clin Oncol; 2021 Oct; 26(10):1901-1910. PubMed ID: 34117554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
    Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
    Front Immunol; 2021; 12():705378. PubMed ID: 34526987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. circHMGCS1-016 reshapes immune environment by sponging miR-1236-3p to regulate CD73 and GAL-8 expression in intrahepatic cholangiocarcinoma.
    Xu YP; Dong ZN; Wang SW; Zheng YM; Zhang C; Zhou YQ; Zhao YJ; Zhao Y; Wang F; Peng R; Tang MC; Bai DS; Huang XY; Guo CY
    J Exp Clin Cancer Res; 2021 Sep; 40(1):290. PubMed ID: 34526098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
    Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
    J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Prognostic Signature Based on Single-Cell RNA Sequencing Data of Immune Cells in Intrahepatic Cholangiocarcinoma.
    Su M; Qiao KY; Xie XL; Zhu XY; Gao FL; Li CJ; Zhao DQ
    Front Genet; 2020; 11():615680. PubMed ID: 33613623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome.
    Tian L; Ma J; Ma L; Zheng B; Liu L; Song D; Wang Y; Zhang Z; Gao Q; Song K; Wang X
    World J Surg Oncol; 2020 Nov; 18(1):303. PubMed ID: 33228682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development.
    Huang X; Tang T; Zhang G; Liang T
    Mol Cancer; 2021 Mar; 20(1):50. PubMed ID: 33685460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Analysis of m5C Methylation Regulatory Genes and Tumor Microenvironment in Prostate Cancer.
    Yu G; Bao J; Zhan M; Wang J; Li X; Gu X; Song S; Yang Q; Liu Y; Wang Z; Xu B
    Front Immunol; 2022; 13():914577. PubMed ID: 35757739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA methylation biomarkers for diagnosis of primary liver cancer and distinguishing hepatocellular carcinoma from intrahepatic cholangiocarcinoma.
    Bai Y; Tong W; Xie F; Zhu L; Wu H; Shi R; Wang L; Yang L; Liu Z; Miao F; Zhao Q; Zhang Y
    Aging (Albany NY); 2021 Jul; 13(13):17592-17606. PubMed ID: 34237708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune infiltrating cells in cholangiocarcinoma may become clinical diagnostic markers: based on bioinformatics analysis.
    Zhang Y; Chen S; Li J; Dai W; Qian Y
    World J Surg Oncol; 2021 Feb; 19(1):59. PubMed ID: 33618734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunity and Extracellular Matrix Characteristics of Breast Cancer Subtypes Based on Identification by T Helper Cells Profiling.
    Zhou Y; Tian Q; Gao H; Zhu L; Zhang Y; Zhang C; Yang J; Wang B
    Front Immunol; 2022; 13():859581. PubMed ID: 35795662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed death ligand 1 expression in human intrahepatic cholangiocarcinoma and its association with prognosis and CD8
    Zhu Y; Wang XY; Zhang Y; Xu D; Dong J; Zhang Z; Yi CH; Jia HL; Yang X
    Cancer Manag Res; 2018; 10():4113-4123. PubMed ID: 30323667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implication of CD69
    Kim HD; Jeong S; Park S; Lee YJ; Ju YS; Kim D; Song GW; Lee JH; Kim SY; Shin J; Shin EC; Hwang S; Yoo C; Park SH
    Liver Int; 2021 Apr; 41(4):764-776. PubMed ID: 33548061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein B Is Associated With the Microenvironment of Cholangiocarcinoma.
    Xu X; Chen D; Feng X; Hu J; Ge J; Yan C; Zhang D; Ling Z; Chen J; Wu J
    Front Oncol; 2021; 11():654689. PubMed ID: 33954113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A2M is a potential core gene in intrahepatic cholangiocarcinoma.
    Zhang G; Liu X; Sun Z; Feng X; Wang H; Hao J; Zhang X
    BMC Cancer; 2022 Jan; 22(1):5. PubMed ID: 34979994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of biomarkers of intrahepatic cholangiocarcinoma via integrated analysis of mRNA and miRNA microarray data.
    Chen Y; Liu D; Liu P; Chen Y; Yu H; Zhang Q
    Mol Med Rep; 2017 Mar; 15(3):1051-1056. PubMed ID: 28098904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of downregulation of WWOX with poor prognosis in patients with intrahepatic cholangiocarcinoma after curative resection.
    Huang C; Tian Y; Peng R; Zhang C; Wang D; Han S; Jiao C; Wang X; Zhang H; Wang Y; Li X
    J Gastroenterol Hepatol; 2015 Feb; 30(2):421-33. PubMed ID: 25168293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.
    Zhou G; Sprengers D; Mancham S; Erkens R; Boor PPC; van Beek AA; Doukas M; Noordam L; Campos Carrascosa L; de Ruiter V; van Leeuwen RWF; Polak WG; de Jonge J; Groot Koerkamp B; van Rosmalen B; van Gulik TM; Verheij J; IJzermans JNM; Bruno MJ; Kwekkeboom J
    J Hepatol; 2019 Oct; 71(4):753-762. PubMed ID: 31195061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.